Transcriptional profile-based subtypes of cancer are often viewed as identifying different diseases from the same tissue origin. Understanding the mechanisms driving the subtypes may be key in development of novel therapeutics but is challenged by lineage-specific expression signals. Using a t-test statistics approach, we compared gene expression subtypes across 12 tumor types, which identified eight transcriptional superclusters characterized by commonly activated disease pathways and similarities in gene expression. One of the largest superclusters was determined by the upregulation of a proliferation signature, significant enrichment in TP53 mutations, genomic loss of CDKN2A (p16 ARF ), evidence of increased numbers of DNA double strand breaks and high expression of cyclin B1 protein. These correlations suggested that abrogation of the P53-mediated apoptosis response to DNA damage results in activation of cell cycle pathways and represents a common theme in cancer. A second consistent pattern, observed in 9 of 11 solid tumor types, was a subtype related to an activated tumor-associated stroma. The similarity in transcriptional footprints across cancers suggested that tumor subtypes are commonly unified by a limited number of molecular themes.
INTRODUCTION
Cancer is a genetic disease in which genomic abnormalities alter the transcriptome, thereby directly or indirectly deregulating the pathways that control proliferation and survival. Large-scale efforts to systematically catalogue the landscape of somatic alterations that contributes to tumorigenesis, such as The Cancer Genome Atlas (TCGA), have shown that extensive genomic heterogeneity within and across tumor types exists, but that alterations in pathways such as the p53 pathway or the receptor tyrosine kinase pathway represent common themes. [1] [2] [3] [4] [5] [6] [7] [8] [9] The transcriptomic diversity in cancer has been captured by robust expression subtypes that are characterized by similarity to gene signatures related to developmental lineages and cellular differentiation. [10] [11] [12] Furthermore, molecular subtypes are frequently found to associate with somatic alterations, such as EGFR abnormalities in the classical subtype of glioblastoma (GBM), 12 or the enrichment of NF1 deletions and mutations in the primitive group of lung squamous carcinoma. 4 Classifying patients into subgroups on the basis of their expression profiles may have clinical relevance including correlations with clinical parameters such as drug response, tumor stage or survival outcome. 13, 14 The associations between transcriptional profile and genomic abnormalities suggest that regulatory networks could be uncovered through integrated analysis of RNA expression, DNA copy number, mutation and other genomic data types. However, this analysis may be hindered by the dominant effect of cellular differentiation on transcription levels, which is unrelated to tumorigenesis. One example is the above-mentioned GBM subtypes, which not only associate with genomic abnormalities but also show preferential activation of different neural cell signatures 12 and may represent different cells of origin or differentiation down alternative neural cell pathways. Similarly, unsupervised clustering of expression profiles from acute myeloid leukemia (LAML) identified associations with the French-American-British classification, which is based on cellular morphology and resemblance to various stages of normal hematopoietic development. 15 By comparing transcriptional signatures across different tumor types, the effects of cellular lineage may be minimized allowing commonalities related to the tumorigenic process to be recognized. For example, TCGA recently reported that the breast carcinoma basal subtype shares genomic as well as transcriptomic features with high-grade serous ovarian cancer (OV), leading to the speculation that therapeutic strategies that are successful in the treatment of ovarian carcinoma may have similar efficacy in the poor prognosis basal breast cancers. 6 We hypothesized that common tumorigenic processes exist across cancer types and that oncogenic pathways can be exposed through pan-cancer comparison of expression subtypes from different tissue origins. To validate our hypothesis, we analyzed the expression profiles of 3444 samples from 12 tumor types, available through The Cancer Genome Atlas consortium. Our analysis identified common components in the expression subtype gene signatures across different tumor types, thereby eliminating the contribution of lineage and exposed the presence of pan-cancer superclusters. Finally, we provided further insights into the molecular basis of these superclusters through annotation with genomic abnormalities, pathway activation scoring and clinical annotation.
RESULTS
Transcriptome-based pan-cancer clustering is primarily driven by tumor lineage and histology To identify pan-cancer gene expression subtypes, we performed unsupervised hierarchical clustering of 3444 expression profiles from 12 different tumor types data sets: LAML (n = 173), bladder urothelial carcinoma (BLCA, n = 96), breast cancer (n = 817), colon adenocarcinoma (COAD, n = 192), rectal adenocarcinoma (READ, n = 71), GBM (n = 154), head and neck squamous cell carcinoma (HNSC, n = 303), clear cell renal cell carcinoma (KIRC, n = 470), lung adenocarcinoma (LUAD, n = 353), lung squamous cell carcinoma (LUSC, n = 220), OV (n = 262) and uterine corpus endometrial carcinoma (UCEC, n = 333) using the top 1500 genes with the largest variance across all samples. Expression data were downloaded from TCGA. Visual inspection of the dendrogram and gene expression heatmap strongly suggested 12 clusters, 10 of which were highly enriched for a specific tumor type ( Figure 1 , Supplementary Table 1 ). Squamous cell carcinoma samples of lung, head and neck, and a subset of BLCA were found in two clusters, suggesting that the squamous histology is a driving force behind these subsets. We obtained gene expression profiles from lung, cervical and esophageal cancers and cell lines from public resources and derived a squamous cell signature by comparing squamous cancers to adenocarcinomas. We used the squamous cell signature to annotate all samples according to their level of 'squamous-ness' and found that cluster eight and nine, containing 87.7% of lung squamous and 99.7% of head and neck squamous cancers, showed high levels of squamous marker expression.
Clusters 11, made up by 22.5% of breast cancers and cluster 12, which included 70.8% of the bladder cancer samples, complemented by 6.8% of renal cancers, 4.5% of lung squamous cancers and 25 tumor samples from all tumor types except LAML, additionally correlated with squamous cell phenotype. In summary, tumor lineage and squamous histology were the major drivers behind the unsupervised clustering across tumor types.
Comparison of expression subtypes across cancer
To be able to extract transcription-based tumorigenic processes without being limited by the dominating influence of tumor lineage, we performed a pan-cancer comparison on the basis of gene expression subtypes. Subtype classification annotation was obtained from the OV, COADREAD, UCEC, LUSC, BLCA, LUAD, GBM, LAML, HNSC and KIRC TCGA disease working groups. To identify expression subtypes of BRCA, we clustered samples for each tumor type using the non-negative matrix factorization (NMF) algorithm on the 1500 variably expressed genes. 16 This resulted in five subtypes for BRCA. In total, 45 expression subtypes were included for further analyses (Supplementary Table 2 ).
To decrease the contributions from tumor lineage and to identify patterns that supersede tumor subtypes, we calculated t-test scores by comparing gene expressions levels of each tumor subtype to other clusters of the same cancer. This resulted in a t-test score matrix of 45 columns (subtypes) and 11 186 rows, representing genes that were common to the four gene expression platforms. To show similarity between expression subtypes, we calculated pairwise Pearson's correlation coefficient for all subtype combinations using the top 1500 genes among tscores, ranked by the median absolute deviation and performed hierarchical cluster analysis of the 45 expression subtypes. We observed the highest correlation density, silhouette scores when cutting the dendrogram tree at eight clusters ( Supplementary  Figures 1-3 ; further details provided in Supplementary Text). The superclusters consisted of at least two subtypes and named them 'supercluster 1' to 'supercluster 8' (Figure 2 ). We did not observe correlations of tissue source site with subtype or supercluster, nor did we find batch effects related to gene expression platforms (data not shown).
To validate the stability and robustness of eight superclusters, we adopted two methods. First, we randomly selected different percentages of samples (50-90%) and used the reduced data sets to evaluate whether superclusters were retained. The validation rate of supercluster formation removing 50, 60, 70, 80 or/and 90% of samples was consistently higher than 90%, suggesting that the superclusters we identified were robust and reproducible. Next, we compared superclusters detected in the TCGA data set with those identified in an independent validation data set. We used subtype gene signatures to classify 2550 expression profiles from publicly available resources (Supplementary Table 3 ). We found that 41 of 45 subtypes were detected in the validation data set and clustering these subtypes showed that five superclusters (supercluster 1, 2, 3, 5 and 8) were retained in their entirety (Supplementary Figure 9 ). Further details are described in the Supplementary Text.
While tumor lineage played a dominant role when clustering individual samples, comparing cancer on the basis of expression subtypes showed extensive intermingling of clusters from different tumor types. Each of the eight superclusters included subtypes from at least two different tumor types. The largest 'supercluster 1' combined subtypes from nine different cancer origins (LAML, BLCA, BRCA, COADREAD, GBM, HNSC, LUSC, OV and UCEC). Correlations between subtypes, which were based on t-test vectors of subtype specific differences in gene expression, ranged between 0.3 and 0.8 in the strongest groups, such as supercluster 1 and supercluster 5 ( Figure 2) . A tumor-associated normal cell supercluster To link superclusters to disease pathways, we used single sample gene set enrichment analysis (ssGSEA) and PAthway Recognition Algorithm using Data Integration on Genomic Models (PARA-DIGM), respectively. 17, 18 ssGSEA quantifies the activation level of a gene set in a particular sample by comparing the expressionbased ranking of genes within the gene set relative to all genes. Gene sets (n = 8513) were obtained from the Molecular Signatures Database (MSigDB version 3.1). 19 ssGSEA scores were calculated for each gene set and each sample. To extract gene sets associated to superclusters, we computed a t-statistic of the ssGSEA scores for each subtype by comparing one subtype versus others, within tumor type. Next, gene sets were ranked in descending order according to the lower quartile of t-test scores among the subtype members of each supercluster (Supplementary Table 4 ). PARADIGM infers integrated pathway activities by integrating transcriptional levels and DNA copy number profiles. 18 We generated integrated pathway activities from 41200 curated signal transduction, transcriptional and metabolic pathways, 20 and estimated a score for each subtype and each integrated pathway activity based on a t-statistic by comparison of one subtype with others per tumor type (Supplementary Table 5 ).
Both ssGSEA and PARADIGM found overrepresented pathways related to 'immune system' or 'cell adhesion' in supercluster 1, suggesting that this supercluster was linked to tumor microenvironment and tumor-associated normal cells ( Figure 3 ). We used our ESTIMATE method to determine the level of infiltrating stromal or immune cells in each sample. 21 As expected, both stromal and Supplementary Figure 1 ). Black and white scaled sidebars indicate the stromal and immune scores 16 and tumor purity inferred using ABSOLUTE 22 for each subtype. immune scores were significantly higher in supercluster 1 compared with other superclusters (stromal score, posthoc maximum P = 0.00065; immune score, posthoc maximum P = 1.3E−15) ( Figure 4 ). The increased level of immune cell scores pertained to the BRCA_4, OV_Immunoreactive, LAML_5 and LUSC_Secretory subtypes, whereas stromal scores were increased in the BLCA_Mesenchymal, HNSC_Mesenchymal, LUSC_secretory, COADREAD_MSI/CIMP, OV_Mesenchymal, GBM_Mesenchymal and LAML_5 classes. The association of supercluster 1 and increased volumes of tumor-associated normal cells was confirmed by relatively lower tumor purity (post hoc maximum P = 0.00867; Figure 4b ), with tumor purity being estimated by applying the ABSOLUTE method on DNA copy number profiles. 22 Cell cycle activation is observed across cancer lineages Supercluster 5 contained subtypes from 6 of the 12 tumor types and ssGSEA and PARADIGM analysis highlighted an association between this set of expression subtypes and increased cell cycle activity (Figure 3 , Supplementary Tables 4 and 5 ). We used reverse phase protein array profiles available for a subset of samples and found that the protein expression levels of mitotic cycle marker cyclin B1 (CCNB1) was significantly upregulated in supercluster 5 relative to other superclusters (P = 1.56E−8) ( Supplementary  Figure 4 ). CCNB1, in complex with cyclin-dependent kinase 1, regulates the G2 phase of the cell cycle during which DNA is checked for chromosome replication errors. 23 We compared the number of DNA copy number segments across subtypes as a proxy for the number of double strand DNA breaks and found a statistically significant increase in the number of copy number segments in association with supercluster 5 (P = 4.78E−7; Supplementary Figure 5 ). In addition to CCNB1, high protein levels of DNA repair gene CHEK2 suggested the presence of DNA damage (P = 4.29E−10), which under normal conditions would direct cells to enter apoptosis. Interestingly, a higher number of mutations in the apoptosis and cell cycle regulator TP53 were observed in supercluster 5 (77% of samples; Figure 5a ), which may explain why cells are not entering apoptosis despite a high level of DNA damage. In addition, all subtypes except OV_Proliferative in supercluster 5 harbored deletions of cyclin-dependent kinase inhibitor 2A (CDKN2A) in more than 10% of samples ( Supplementary Figure 6 , Supplementary Tables 6 and 7) . Supercluster 5 member LUAD_Magnoid did not harbor many TP53 mutations, but instead correlated to a high frequency of CDKN2A/ CDKN2B homozygous deletions (62.5% of samples; Figure 5b ), which control the G1 cell cycle phase (Figure 5c ). The association between TP53 mutation and CDKN2A deletion showed a trend toward mutually exclusivity (Fisher's exact test, P = 0.10). A similar set of significant observations was made for supercluster 7. This supercluster consisted of a BRCA and a UCEC subtype, two tumor types that were not found among supercluster 5 members. In addition to protein expression of CCNB1, supercluster 7 showed higher expression of CCNE1 (P = 2.08E−22 and 4.6E−17) and lower expression of CCND1 compared with the other superclusters (P = 9.58E−10) ( Supplementary Figure 4 ). Furthermore, a significantly increased frequency of MYC amplification was observed in supercluster 7 (BRCA_2, P = 0.000018; UCEC_Mitotic, P = 0.0027; Supplementary Figure 6 , Supplementary Table 8) , which leads to cell cycle progression and potentially distinguished supercluster 7 from supercluster 5. In summary, these results suggested that supercluster 5 and supercluster 7 are dominated by somatic alterations that affect the G2-M phase and S-phase of the cell cycle, respectively (Figure 5c ).
Common molecular characteristics of superclusters were associated with clinical outcome To examine whether superclusters were consistently associated with survival, we compared clinical outcome between superclusters (Cox proportional hazards survival regression analysis, hazard ratios and 95% confidence intervals, Supplementary Figure 7A ). An important aspect of this analysis is that we accounted for differences in survival between tumor types by normalizing outcome measures within each tumor type, and Figure 4 . The presence level of stromal and immune cells in tumor tissues per each subtype. Boxplots of (a) stromal and immune scores, (b) tumor purity scores per subtype revealed the different distribution of each score among superclusters. The x axis denotes subtypes and the y axis represents stromal, immune and tumor purity scores that were z-transformed per each tumor type.
Pan-cancer gene expression patterns evaluated whether multiple subtype members of the same supercluster were showing a similar direction in outcome. Two significant correlations were observed. The BRCA_1 and LUAD_-Bronchoid subtypes, which combined made up supercluster 2, associated with better prognosis (BRCA_1, P = 0.1; LUAD_Bronchioid, P = 0.02) and corresponding to the relatively favorably outcome, we noted that 79.2% of these samples were diagnosed as early stage (stage I/II) ( Supplementary Table 9 ). In contrast, three of five subtypes in supercluster 8 correlated with adverse outcome (KIRC_3, P = 0.0012; LUAD_Squamoid, P = 0.06; BRCA_3, P = 0.00017). These subtypes had in common pathways related to SHC1 events in EGFR and ERBB4 signaling, which are related to drug resistance as well as pro-mitotic and survival pathways. 24, 25 We did not find consistent associations between superclusters and demographics such as age and gender (Supplementary Figure 7B , and Supplementary Table 9 ).
DISCUSSION
Here, we presented a comprehensive pan-cancer comparison of transcriptional patterns across 12 different tumor types. Unsupervised analysis of cancer expression profiles showed the dominating effects of tumor lineage and histology on cluster formation. However, comparing cancers using molecular subtype profiles revealed the presence of recurrent disease-related expression patterns. These findings suggest that grouping tumor samples on the basis of their transcriptional profile, which has been described for many tumor types, 10, 11, 15, 26 generally follows a limited number of themes, some of which we have identified as occurring across tumor lineage. A parallel study by Hoadley et al (in press) clustered largely the same TCGA data set using integrated molecular profiles ('COCA'---clusters) and found a class consisting of TP53-mutated HSNC-LUSC-BLCA tumors, in addition to several other pan-cancer clusters.
We observed a supercluster characterized by presence of tumor-associated normal cells, which included subtypes from 9 of 11 solid tumors. The role of the tumor microenvironment is increasingly being appreciated, most prominently as immunotherapeutics such as anti-PD1 and anti-CTL4A that have shown efficacy in advanced melanoma and other tumor types. [27] [28] [29] [30] The persistent presence of subsets of stroma-associated and immunecell-associated tumors across many cancers may suggest a role for microenvironment-produced growth factors. Alternatively, these tumors may produce chemotactic factors that attract tumorassociated normal cells. Whether the presence of increased number of immune cells will signal responsiveness to immunomodulatory therapeutics will need to be assessed clinically for this subset of tumors. A second large supercluster, plus a third smaller supercluster, unified the cell cycle and apoptosis pathways, through combined presence of an increased level of DNA double strand breaks, mutations in TP53, loss of CDKN2A and cell cycle protein levels. Although TP53 mutations are frequent across cancer lineages and may generally serve an anti-apoptotic role, we speculate that in the context of the proliferation transcriptomic signature, these mutations were selected to negate the apoptotic signals resulting from high levels of DNA damage. The resulting protein and gene expression signature reflect the consequences of an altered cell cycle pathway. However, our observations do not necessarily indicate that targeting of the cell cycle pathway by means of CDK4/CDK6 inhibitors will be more effective in supercluster 5/supercluster 7 tumors than in other cancers as it is unclear that the observed pathway changes are functional or a consequence of changes in proliferation and viability. Further comparative experiments of cell cycle performance metrics, such as cell proliferation assays, are needed to show that increased cell cycle pathway activity is associated with increased proliferation.
Although we were able to identify some correlations with patient outcomes in superclusters, we were unable to identify a consistent pattern of clinical outcome in relation to superclusters. It is important to note that the survival data in several TCGA data sets is limited by the length of follow up. 6 In summary, comparison of large numbers of gene expression profiles across many tumor types highlights the relevance of a number of transcriptional footprints that unify a decade of cancer subtype research.
MATERIALS AND METHODS

Data preparation
The TCGA level 3 for gene mutation, copy number and expression data were downloaded from TCGA Data portal (https://tcga-data.nci.nih.gov/ tcga/). Twelve tumor types (acute myeloid lymphoma, BLCA, breast carcinoma, COAD, rectal adenocarcinoma, GBM, HNSC, KIRC, LUAD, LUSC, ovarian serous cystadenocarcinoma, and UCEC) from four platforms (Agilent G4502A; Affymetrix HG-U133Plus2.0; Affymetrix HT-HG-U133A; Illumina HiSeq) were used in this study (Table 1) .
Cluster assignments and consensus clustering using non-negative matrix factorization
We used the molecular classification provided by the TCGA disease analysis working group of 11 out of 12 tumor types ( Table 1 ). As consensus clustering was originally used for cancer subtype discovery studies in TCGA, we applied consensus clustering using NMF 16 to the breast cancer Agilent expression data. The NMF algorithm is a linear algebra matrix factorization algorithm that depends on the initialization and a parameter k representing the number of clusters. Thus, the consensus clustering algorithm was ran 100 times reporting highly stable clusters. We used the top~1500 genes (as used in previous TCGA papers) ranked according to the median absolute deviation to run NMF over each of the three tissues that did not have TCGA subtype information. The number k of clusters (subtypes) was chosen using the cophenetic correlation coefficient; approximated ties were resolved by maximizing the number of clusters and samples per cluster. We did not use PAM50 signature to obtain breast cancer subtypes because PAM50 signature is not based on consensus clustering and is applied to real-time PCR-based expression. 31 However, Supplementary Table 10 shows some overlap between PAM50 subtypes and our NMF subtypes.
Scoring the presence level of tumor-associated normal cells and the extent of squamous cell phenotype using gene expression data Stromal and immune scores were defined by ESTIMATE algorithm. 21 Briefly, through comparison of tumor samples with high presence of tumorassociated stroma, and infiltrating leukocytes, as well as cell sorting of tumor samples, we generated a signature predictive of presence of stroma and a signature predictive of the presence of immune cells, using ssGSEA. 17 We calculated ssGSEA scores for our stromal and immune signatures that predicted the presence level of stromal and immune cells in the tumor tissue. We also used the purity predictions generated by the ABSOLUTE algorithm, 22 which uses DNA copy number data to infer tumor purity. The data were obtained from TCGA pan-cancer data set. 32 To identify a squamous signature specifically related to the presence of squamous cell carcinoma, four microarray data sets were obtained from the Gene Expression Omnibus (GSE10245, lung cancer; GSE28571, lung cancer; GSE26886, esophageal cancer and GSE27388, cervical cancer). Next, the significance analysis of microarray 33 method was used to detect significantly upregulated expressed genes (4 twofold and qo0.0001) in the squamous cell carcinoma group compared to adenocarcinoma group for each microarray data set. For those three respective data sets, we extracted 226, 419, 189 and 99 upregulated genes in squamous cell carcinomas. In total, 254 squamous-related genes were identified in at least two data sets. Next, to consider the influence of tumor purity, we extracted 97 upregulated genes in squamous cell carcinoma cell lines (n = 26) compared to adenocarcinoma cell lines (n = 49) from the CCLE expression data set. 34 Of these, we selected 25 overlapping genes involved in squamous cell carcinoma. Finally, one gene was excluded as it was previously found to be associated with 'normal hematopoietic-cell related genes', 21 resulting in a final set of 24 squamous cell carcinoma-related genes (squamous signature). We confirmed that ssGSEA scores for this signature (named as 'squamous score') could detect squamous cell phenotype in a validation data set (GSE2109), that consisted of 66 squamous cell carcinomas, 9 adenosquamous cell carcinomas, 2 adenocarcinomas with squamous differentiation and 1311 non-squamous cell carcinomas.
Supercluster identification and validation
To identify superclusters, we first generated t-statistics for all genes, by comparing gene expression levels of each subtype and the other subtypes Pan-cancer gene expression patterns of the same tumor type. This resulted in t-statistic vectors for each of the 45 gene expression subtypes from 12 tumor types. We then calculated Pearson's correlation between all tissue subtypes, using the t-statistic vectors. Then, we applied hierarchical clustering using squared Euclidean distance. 35 To maximize the tightness within clusters we used complete agglomeration. To generate the clusters, we cut the tree using the following criteria: (i) maximize the average or minimize the negative silhouette scores among clusters, (ii) maximize the correlation among clusters, (iii) include clusters composed of more than one tissue minimizing the number of subtypes from the same tissue and (iv) obtain the least number of clusters.
To validate superclusters we used two methods: (i) removing different percentages of samples and identifying superclusters using the reduced data sets and (ii) identifying superclusters on other public data sets.
The first method is similar to the one used to validate oncogenic signatures for multiple cancers. 36 For each tissue, we removed 10-50% of the samples 100 times each. We calculated the frequency of times two subtypes coincided in the same cluster and then identified supeclusters using this frequency (as a correlation measure) and cutting the hierarchical tree to obtain the same number of clusters as for the original TCGA data. Finally, we compared if the superclusters identified from the reduced data sets were similar to the original superclusters.
We also validated superclusters using public data. Supplementary Table  11 shows the data sets used for this experiment. For each tumor type, we selected these data sets from Affymetrix HG-U133 Plus 2.0 based gene expression data with maximum sample size in Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) and ArrayExpress (http://www.ebi.ac. uk/arrayexpress/). To avoid batch effect, we did not merge some public data sets in the same tumor type. The public data sets have a total of 2550 samples. To identify superclusters on public data sets, we first assigned a subtype to each respective tissue sample and then identify superclusters cutting the hierarchical tree similar as for original data. As for the reduced data sets, then we matched the superclusters acquired using public data sets to the original superclusters.
The Supplementary Text contains further details on the process to identify and validate superclusters.
TCGA subtype definition for public data
In order to use public data, we needed to classify samples according to TCGA subtypes. Therefore, we first obtained subtype signatures for each tissue. If available, subtype signature were extracted from the TCGA respective tissue publications. Otherwise, we ran significance analysis of microarray 33 comparing one subtype versus the others and selected the top 200 upregulated genes. For BLCA, BRCA, COADREAD, LUAD, LUSC and UCEC, subtypes signatures were derived from the top 200 significance analysis of microarray genes. For GBM, HNSC, KIRC, LAML and OV, we used the subtypes signatures from the respective publication. 1, [3] [4] [5] [6] [7] [8] [9] 12, 14 We tested two classification algorithms, PAMR 37 and SVM, 38 on the TCGA data and selected the most accurate per tissue using a 10-fold cross validation scheme. Supplementary Table 12 shows SVM was selected for all tissues except LUSC.
Identification of statistically significant differences in genetic alterations per subtype
To associate subtypes within superclusters to DNA alterations (somatic mutations, focal amplifications and homozygous deletions), we counted alterations per subtype and used a chi-square test to test for overrepresentation relative to the remaining samples of that tumor type. As we were looking for overrepresentations, we avoided cases where counts were lower than expected setting its P-value to 1. Only DNA alterations that involve genes and samples included in gene expression data were considered.
For mutation data, we ignored 'Silent', 'Non-stop mutation' or 'RNA' mutations. For copy number variation data, we used TCGA discretized (values − 2, − 1, 0, 1 and − 2) and transformed the data to − 1, 0 and +1 representing deletions, no alteration and focal amplifications, respectively, which were independently evaluated.
To select gene alterations associated to a supercluster, we ranked the genes according to a conservative P-value, which was estimated by the first quartile of included subtypes P-values. This will highlight genes having alterations in more than one subtype.
Genomic relationships in supercluster
To identify the similarity of genetic alterations (mutations, amplification and homozygous deletions) in supercluster 5 and 7, we first extracted genes genetically altered in at least 10% of each subtype composed of supercluster 5 and 7. Of extracted genes, we selected overlapped genes among more than three-fourth subtypes within supercluster 5 or 7, respectively. By comparing the frequency of altered samples per gene between supercluster 5, 7, and the others, we found the similarity of genetic alterations in supercluster 5 and 7.
Gene set enrichment analysis using ssGSEA To find gene sets related to superclusters, we ran ssGSEA. We transformed the ssGSEA sample scores to estimate a subtype t-statistic by comparing each subtype to the other subtypes of the same tissue. We used 9707 gene sets obtained from MSigDB 19 (n = 8513) plus subsets generated by combining upregulated and downregulated genes having the same subset name. To avoid intrinsic similarity between gene sets, we filtered out gene sets whose jaccard coefficient index was higher than 0.7 resulting in 8907 gene sets. The results from this filtering are indicated as 'jaccard' in Supplementary Table 4 . Also, we reported the results from using the complete list of gene sets (identified as 'complete' in Supplementary Table  4 ). To achieve clearer biological insights, we focused on canonical pathways belonging to Biocarta, Reactome, 39 KEGG 40 and PID 41 ('canonical' in Supplementary Table 4 ).
To select gene sets related to a supercluster, gene sets were ranked by a representative t-statistic, which was estimated by the first quartile from the subtypes of t-statistics belonging to the supercluster. This would emphasize gene sets having consistently high t-statistics (and thus higher ssGSEA scores) along the supercluster.
Pathway activity analysis using PARADIGM
The PARADIGM algorithm 18 estimates pathway activities levels per sample from curated biological entities modeling the process of transcription, translation and protein activation considering data as evidence under probabilistic inference. We used expression and copy number alteration data to run PARADIGM. We initially used 56 418 entities covering~1250 pathways. Similar to the ssGSEA analysis, pathways whose jaccard coefficient index were higher than 0.7 were filtered. We kept those pathways with a higher number of entities, which provide better description of the pathway. We also filtered PARADIGM output entities that were repeated in the same pathway. We finally used 42 214 entities corresponding to~1000 pathways.
Similarly to ssGSEA analysis, PARADIGM sample scores were transformed to subtype t-statistics. To focus on activated PARADIGM entities, entities were selected according to a summary supercluster t-statistic, which was estimated from the first quartile from the t-statistics of the subtypes belonging to the supercluster. Only entities having positive t-statistic in all supercluster subtypes were considered. This will select entities that are consistently positive values in all subtypes of the supercluster. To select PARADIGM pathways related to superclusters, we used a hypergeometric test to evaluate the likelihood of observing a high number of selected entities from a pathway. Supplementary Table 5 show the entities and pathways resulted from this analysis.
Validation of activated cell cycle using protein expression.
We downloaded reverse-phase protein array expression data (syn1710429), which composed of 205 total and phosphorylated proteins, from Synapse BETA (https://www.synapse.org/). Of the 2704 samples, 2125 common samples between mRNA expression data and reverse phase protein array data (BLCA, n = 51; BRC, n = 407; COADREAD, n = 124; GBM, n = 184; HNSC, n = 206; KIRC, n = 384; LUAD, n = 181; LUSC, n = 111; OV, n = 288; UCEC, n = 189) were used in the subsequent analysis. To compare cell-cyclerelated proteins across different tumor types, we performed z-transformation per each tumor type.
Evaluation of genomic instability
We used TCGA level 3 copy number alteration data based on Affymetrix SNP 6 to calculate the number of segments per each sample. To compare the number of segments across different tumor types, we excluded samples with extreme number of segments that were detected by using the generalized extreme studentized deviate (GESD) test 42 and performed z-transformation per each tumor type.
Statistical analysis
We conduced all computations with R 2.13.2, 43 and used standard statistical tests as appropriate, including Pearson's correlation analysis, unpaired t-test, one-way ANOVA, Fisher's exact test and Cox proportional hazards univariate analysis. We downloaded TCGA clinical information on March 2013 from TCGA data portal [https://tcga-data.nci.nih.gov/tcga/].
